Skip to main content

Advertisement

SpringerLink
Log in

Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing’s disease

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Several complications associated with active Cushing’s disease may persist even years after complete and successful therapeutic remission of hypercortisolism. Growth hormone deficiency (GHD) shares many clinical features seen in patients with Cushing’s disease, and its presence after disease remission (GHD-CR) might negatively influence and potentially worsen the systemic complications caused by previous hypercortisolism. GHD-CR is more prevalent in women, and compared to other causes of GHD, patients are younger at the onset of the pituitary disease, at diagnosis of GHD-CR and at start of GH therapy; prevalence of pituitary macroadenomas and visual abnormalities are lower, while prevalence of diabetes, hypertension, low bone mass, fractures, and worst quality of life, are higher. Serum IGF-1 levels are not useful for the diagnosis of GHD-CR and the application of GH stimulating tests requires some special attention in addition to the general recommendations for detecting GHD from other etiologies. In patients with active hypercortisolism, GH secretion is completely suppressed, but it may spontaneously and progressively recover over the years following successful therapy, meaning that GH testing may be performed at an appropriate time after remission for the correct diagnosis. Moreover, if the patient presents concomitant adrenal insufficiency, GH testing should only be carried out under adequate cortisol replacement therapy. GH therapy in children with GHD-CR improves adult height in the majority of patients, while GH therapy in adults has been associated with improvements in body composition, lipid profile and quality of life, but also with worsening of glucose metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A (2016) Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol 4(7):611–629

    Article  CAS  Google Scholar 

  2. Formenti AM, Maffezzoni F, Doga M, Mazziotti G, Giustina A (2017) Growth hormone deficiency in treated acromegaly and active Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 31(1):79–90

    Article  CAS  Google Scholar 

  3. Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9(5):265–276

    Article  CAS  Google Scholar 

  4. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK (2021) Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847–875

    Article  Google Scholar 

  5. Tzanela M, Karavitaki N, Stylianidou C, Tsagarakis S, Thalassinos NC (2004) Assessment of GH reserve before and after successful treatment of adult patients with Cushing’s syndrome. Clin Endocrinol (Oxford) 60(3):309–314

    Article  CAS  Google Scholar 

  6. Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Ståhl E, Monson JP, Westberg B, Wilton P, Wüster C, KIMS (2002) International study board of KIMS study group growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing’s disease. Eur J Endocrinol 146(1):67–74

    Article  CAS  Google Scholar 

  7. Webb SM, Mo D, Lamberts SW, Melmed S, Cavagnini F, Giraldi FP, Strasburger CJ, Zimmermann AG, Woodmansee WW (2010) International HypoCCS advisory board metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing’s disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab 95(2):630–638

    Article  CAS  Google Scholar 

  8. Höybye C, Ragnarsson O, Jönsson PJ, Koltowska-Häggström M, Trainer P, Feldt-Rasmussen U, Biller BM (2010) Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing’s disease. Eur J Endocrinol 162(4):677–684

    Article  Google Scholar 

  9. Carroll PV, Monson JP, Grossman AB, Besser GM, Plowman PN, Afshar F, Savage MO (2004) Successful treatment of childhood-onset Cushing’s disease is associated with persistent reduction in growth hormone secretion. Clin Endocrinol (Oxford) 60(2):169–174

    Article  CAS  Google Scholar 

  10. Hughes NR, Lissett CA, Shalet SM (1999) Growth hormone status following treatment for Cushing’s syndrome. Clin Endocrinol (Oxford) 51(1):61–66

    Article  CAS  Google Scholar 

  11. Giraldi FP, Andrioli M, De Marinis L, Bianchi A, Giampietro A, De Martin M, Sacco E, Scacchi M, Pontecorvi A, Cavagnini F (2007) Significant GH deficiency after long-term cure by surgery in adult patients with Cushing’s disease. Eur J Endocrinol 156(2):233–239

    Article  CAS  Google Scholar 

  12. Mukherjee A, Murray RD, Teasdale GM, Shalet SM (2004) Acquired prolactin deficiency (APD) after treatment for Cushing’s disease is a reliable marker of irreversible severe GHD but does not reflect disease status. Clin Endocrinol (Oxford) 60(4):476–483

    Article  CAS  Google Scholar 

  13. Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR (2019) American association of clinical endocrinologists and american college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract 25(11):1191–1232

    Article  Google Scholar 

  14. Ragnarsson O, Höybye C, Jönsson PJ, Feldt-Rasmussen U, Johannsson G, Biller BM, Koltowska-Häggström M (2012) Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing’s disease or non-functioning pituitary adenomas during childhood. Eur J Endocrinol 166(4):593–600

    Article  CAS  Google Scholar 

  15. Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F, Plowman PN, Grossman AB, Savage MO (2005) Final adult height and body mass index after cure of paediatric Cushing’s disease. Clin Endocrinol (Oxford) 62(4):466–472

    Article  CAS  Google Scholar 

  16. Colson A, Brooke AM, Walker D, Besser GM, Chew SL, Grossman AB, Jenkins PJ, Drake WM, Monson JP (2006) Growth hormone deficiency and replacement in patients with treated Cushing’s disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Horm Res 66(6):257–267

    CAS  PubMed  Google Scholar 

  17. Johannsson G, Sunnerhagen KS, Svensson J (2004) Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing’s disease. Clin Endocrinol (Oxford) 60(5):550–559

    Article  CAS  Google Scholar 

Download references

Funding

No funding was received to assist with the preparation of this manuscript.

Author information

Authors and Affiliations

  1. SEMPR (Endocrine Division), Department of Internal Medicine, Federal University of Parana, Agostinho Leão Junior 285, Curitiba, PR, 80030-110, Brazil

    Cesar Luiz Boguszewski

Authors
  1. Cesar Luiz Boguszewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CLB: responsible to write the main manuscript text and the table.

Corresponding author

Correspondence to Cesar Luiz Boguszewski.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boguszewski, C.L. Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing’s disease. Pituitary 25, 760–763 (2022). https://doi.org/10.1007/s11102-022-01225-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-022-01225-z

Keywords

Search

Navigation